Literature DB >> 8005672

Development of destructive arthritis in vaccinated hamsters challenged with Borrelia burgdorferi.

L C Lim1, D M England, B K DuChateau, N J Glowacki, J R Creson, S D Lovrich, S M Callister, D A Jobe, R F Schell.   

Abstract

We present the first direct evidence that adverse effects, particularly severe destructive arthritis, can develop in vaccinated hamsters after challenge with Borrelia burgdorferi sensu lato isolates. Hamsters were vaccinated with a whole-cell preparation of Formalin-inactivated B. burgdorferi sensu stricto isolate C-1-11 in adjuvant. A severe destructive arthritis was readily evoked in vaccinated hamsters challenged with the homologous B. burgdorferi sensu stricto isolate C-1-11 before high levels of protective borreliacidal antibody developed. Once high levels of C-1-11 borreliacidal antibody developed, hamsters were protected from homologous challenge and development of arthritis. Vaccinated hamsters, however, still developed severe destructive arthritis when challenged with other isolates of the three genomic groups of B. burgdorferi sensu lato (B. burgdorferi sensu stricto isolate 297, Borrelia garinii isolate LV4, and Borrelia afzelii isolate BV1) despite high levels of C-1-11 specific borreliacidal antibody. Vaccines that contained whole spirochetes in adjuvant induced destructive arthritis, but this effect was not dependent on the isolate of B. burgdorferi sensu lato or the type of adjuvant. These studies demonstrate that caution is necessary when employing whole spirochetes in adjuvant for vaccination to prevent Lyme borreliosis. Additional studies are needed to identify the antigen(s) responsible for the induction and activation of arthritis and to define the immune mechanisms involved.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8005672      PMCID: PMC302888          DOI: 10.1128/iai.62.7.2825-2833.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  54 in total

1.  Performance of a Borrelia burgdorferi bacterin in borreliosis-endemic areas.

Authors:  S A Levy; B A Lissman; C M Ficke
Journal:  J Am Vet Med Assoc       Date:  1993-06-01       Impact factor: 1.936

2.  Seroprotective groups among isolates of Borrelia burgdorferi.

Authors:  S D Lovrich; S M Callister; L C Lim; R F Schell
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

3.  Animal and human antibodies reactive with the outer surface protein A and B of Borrelia burgdorferi are borreliacidal, in vitro, in the presence of complement.

Authors:  V Sambri; S Armati; R Cevenini
Journal:  FEMS Immunol Med Microbiol       Date:  1993-06

4.  Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three connecticut communities.

Authors:  A C Steere; S E Malawista; D R Snydman; R E Shope; W A Andiman; M R Ross; F M Steele
Journal:  Arthritis Rheum       Date:  1977 Jan-Feb

5.  Immunological and molecular polymorphisms of OspC, an immunodominant major outer surface protein of Borrelia burgdorferi.

Authors:  B Wilske; V Preac-Mursic; S Jauris; A Hofmann; I Pradel; E Soutschek; E Schwab; G Will; G Wanner
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

6.  Distinct patterns of protective antibodies are generated against Borrelia burgdorferi in mice experimentally inoculated with high and low doses of antigen.

Authors:  U E Schaible; L Gern; R Wallich; M D Kramer; M Prester; M M Simon
Journal:  Immunol Lett       Date:  1993-05       Impact factor: 3.685

7.  Variability of osp genes and gene products among species of Lyme disease spirochetes.

Authors:  R T Marconi; M E Konkel; C F Garon
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

8.  Cross-reactivity between Borrelia burgdorferi flagellin and a human axonal 64,000 molecular weight protein.

Authors:  L H Sigal
Journal:  J Infect Dis       Date:  1993-06       Impact factor: 5.226

9.  Protection against antigenically variable Borrelia burgdorferi conferred by recombinant vaccines.

Authors:  S R Telford; E Fikrig; S W Barthold; L R Brunet; A Spielman; R A Flavell
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

10.  Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine.

Authors:  C K Stover; G P Bansal; M S Hanson; J E Burlein; S R Palaszynski; J F Young; S Koenig; D B Young; A Sadziene; A G Barbour
Journal:  J Exp Med       Date:  1993-07-01       Impact factor: 14.307

View more
  28 in total

1.  Outer surface protein A and arthritis in hamsters.

Authors:  D L Parenti
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

2.  Macrophages exposed to Borrelia burgdorferi induce Lyme arthritis in hamsters.

Authors:  B K Du Chateau; D M England; S M Callister; L C Lim; S D Lovrich; R F Schell
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

3.  Occurrence of severe destructive lyme arthritis in hamsters vaccinated with outer surface protein A and challenged with Borrelia burgdorferi.

Authors:  C L Croke; E L Munson; S D Lovrich; J A Christopherson; M C Remington; D M England; S M Callister; R F Schell
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

Review 4.  Lyme arthritis: current concepts and a change in paradigm.

Authors:  Dean T Nardelli; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2007-11-14

5.  Production of borreliacidal antibody to outer surface protein A in vitro and modulation by interleukin-4.

Authors:  E L Munson; B K Du Chateau; D A Jobe; S D Lovrich; S M Callister; R F Schell
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

6.  Anti-CD25 antibody treatment of mice vaccinated and challenged with Borrelia spp. does not exacerbate arthritis but inhibits borreliacidal antibody production.

Authors:  Dean T Nardelli; Thomas F Warner; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2006-08

7.  Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi.

Authors:  Y F Chang; M J Appel; R H Jacobson; S J Shin; P Harpending; R Straubinger; L A Patrican; H Mohammed; B A Summers
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

8.  Involvement of CD4+ T lymphocytes in induction of severe destructive Lyme arthritis in inbred LSH hamsters.

Authors:  L C Lim; D M England; N J Glowacki; B K DuChateau; R F Schell
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

Review 9.  Biology of infection with Borrelia burgdorferi.

Authors:  Kit Tilly; Patricia A Rosa; Philip E Stewart
Journal:  Infect Dis Clin North Am       Date:  2008-06       Impact factor: 5.982

10.  Gamma interferon inhibits production of Anti-OspA borreliacidal antibody in vitro.

Authors:  Erik L Munson; Brian K Du Chateau; Jani R Jensen; Steven M Callister; David J DeCoster; Ronald F Schell
Journal:  Clin Diagn Lab Immunol       Date:  2002-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.